Mediterranean Diet and Atherothrombosis Biomarkers: A Randomized Controlled Trial

Identificador:  imarina:8366433

Handle: https://hdl.handle.net/20.500.11797/imarina8366433

Autors:  Hernaez, Alvaro; Castaner, Olga; Tresserra-Rimbau, Anna; Pinto, Xavier; Fito, Montserrat; Casas, Rosa; Martinez-Gonzalez, Miguel Angel; Corella, Dolores; Salas-Salvado, Jordi; Lapetra, Jose; Gomez-Gracia, Enrique; Aros, Fernando; Fiol, Miquel; Serra-Majem, Lluis; Ros, Emilio; Estruch, Ramon

Resum:
To assess whether following a Mediterranean diet (MedDiet) improved atherothrombosis biomarkers in high cardiovascular risk individuals.In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, we assessed the 1-year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; n = 120) or nuts (MedDiet-Nuts; n = 119) versus a low-fat control diet (n = 119). We also studied whether large increments in MedDiet adherence (?3 score points, relative to compliance decreases) and intake changes in key food items were associated with 1-year differences in biomarkers. We observed differences between 1-year changes in the MedDiet-VOO intervention and control diet on the activity of platelet activating factor acetylhydrolase in HDLs (+7.5% [95% confidence interval: 0.17; 14.8]) and HDL-bound ?1 -antitrypsin levels (-6.1% [-11.8; -0.29]), and between the MedDiet-Nuts intervention and the control arm on non-esterified fatty acid concentrations (-9.3% [-18.1; -0.53]). Large MedDiet adherence increments were associated with less fibrinogen (-9.5% [-18.3; -0.60]) and non-esterified fatty acid concentrations (-16.7% [-31.7; -1.74]). Increases in nut, fruit, vegetable, and fatty fish consumption, and decreases in processed meat intake were linked to beneficial changes in atherothrombosis biomarkers.Following a MedDiet improved atherothrombosis biomarkers in high cardiovascular risk individuals. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.